key: cord-0790429-nnzfz4vf
authors: Ichikawa, T.; Torii, S.; Suzuki, H.; Takada, A.; Suzuki, S.; Nakajima, M.; Tampo, A.; kakinoki, y.
title: Mutations on non-structural proteins of SARS-CoV-2 are possibly responsible for adverse clinical outcomes in a real-life practice
date: 2021-10-20
journal: nan
DOI: 10.1101/2021.10.19.21265062
sha: cf7f85a0fd6b850e066fb9f6daaf9406fadb2a1a
doc_id: 790429
cord_uid: nnzfz4vf

Among a single COVID-19 cluster population from the end of March through April 2021 in Asahikawa, we experienced the cases in which patients manifested severe clinical symptoms compared to patients who were infected before that. A hundred three patients (age range: 65 to 89 years old) enrolled in this study were divided into two groups, group A: the patients infected from November 2020 to March 2021, and group B: the patients in this cluster population. The mortality rates were 6.1% in group A and 16.2% in group B (OR: 2.97, 95%CI: 0.65-15.38). For the severity of disease, the patients in group B reached to the clinical state which requires higher oxygen flow rate more quickly (mild; p=0.892, moderate; p=0.117, severe; p=0.029). Whole viral genome sequences revealed five non-synonymous mutations by comparison of the isolates with each group. Of these, four were on NSPs including nsp3, 6 and 15, and one was on S protein located near the C-terminus, suggesting that mutations on NSPs could be responsible for adverse clinical outcomes in COVID-19 patients.

to be associated with increase in transmissibility or virulence 48 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). For example, VOC-202012/01 49 (pango lineage B.1.1.7), as it is called "alpha variant", has higher transmissibility and mortality 50 compared to a reference isolate [5, 6] . These variants, however, were not focused on mutations in NSPs, 51 but in structural proteins, especially S protein. It remains unclear whether mutations in NSPs are 52 responsible for the virulence of COVID-19. 53

As of October 2021, COVID-19 is responsible for 1.7 million cases and 18 thousand deaths 54

in Japan (https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html). The most remarkable 55 clinical feature of this disease is its heterogeneity in clinical manifestations, ranging from no symptoms 56 to critical illness [7] . Several risk factors for symptom severity have been known, such as age (over 57

The stored RNA extracts were used as clinical samples. Fist-strand cDNA was synthesized by using a 97

PrimeScript IV 1 st strand cDNA Synthesis Mix (TaKaRa Bio) with random hexamer primers and 98 extracted RNA, according to the manufacture's protocols. The whole-genome sequencing of SARS-99

CoV-2 was carried out as reported previously [13] . Briefly, a total of 10 gene fragments were amplified 100 with synthesized cDNA, specific primer sets for SARS-CoV-2 and PrimeSTAR GXL DNA 101 polymerase (TaKaRa Bio). Then, the amplified products were directly sequenced in both directions by 102 using the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems) with specific primers. Our raw 103 sequence data were converted to FASTQ format by in-house Python script with BioPython module 104

[14], followed by trimming first 50 bps and the region after 900 bps by FASTX-Toolkit 105 (http://hannonlab.cshl.edu/fastx_toolkit/). Trimmed sequence reads were mapped to the SARS-CoV-2 106 reference genome (accession number MN908947.3). 107 (https://www.ncbi.nlm.nih.gov/books/NBK25497/). Sequences including less than 29,000 definite 113 bases, neither 'N' nor other mixed bases, were discarded. 114

All SARS-CoV-2 genome sequence data, including our assemblies, were mapped to the 115 reference genome (accession number MN908947.3). Based on the SAM format mapping output, SNPs 116 and short INDELs were detected and categorized to synonymous, non-synonymous or intergenic 117 mutations by in-house Perl scripts, which simply picked up the differences from the reference 118 sequence for each genome. For the phylogenetic analysis, a typical genome sequence of each variant, 119 named alpha, beta, gamma, delta, epsilon, zeta, eta, theta, iota, kappa, and lambda by WHO, were 120 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in were included in open reading frames (ORFs), number of substitution sites in ORFs were less than 122 100, all non-synonymous mutations which characterize each variant were included, and all other 123 substitutes observed in more than 95% of the samples that satisfy the above conditions were also 124 included. The non-synonymous mutations which characterize each variant are shown in Table S1 , 125 created based on the mutation prevalence information from outbreak.info (https://outbreak.info/). 126 ORF10 was excluded from the analyses because one of our assemblies did not completely cover that 127 region. Based on the alignment, suitable nucleotide substitution models for each partition were 128 selected by ModelTest-NG [15], followed by maximum likelihood phylogenetic analyses using the 129 selected substitution models by RAxML-NG [16] . The constructed phylogenetic tree was drawn and 130

November 2020 to March 2021, and group B: the patients whose infection was traced from the cluster 147 K. We included the patients whose ages range between 65 and 89 years old for the following reasons; 148 1) patients who are younger than 65 years old are not necessarily requested for hospitalization in our 149 health care system, 2) in group A, many patients over 90 years old were transferred from a 150 convalescent hospital where COVID-19 outbreak had occurred, thus the age profiles would be much 151 different from group B if the patients aged over 90 years old were included in this group. Finally, 66 152 patients were assigned to group A and 37 patients to group B (Figure 1 ). 153

The clinical characteristics and treatment strategies used during hospitalization are shown 154

in Table 1 . Although there were no significant differences in clinical characteristics between the two 155 groups, obesity and lifestyle-related diseases such as hypertension, dyslipidemia and diabetes tended 156 to be more prevalent in group B. In treatment strategies, remdesivir tended to be used more frequently Asahikawa_0417 isolated in April 2021. The mutation sites which differed in these four samples are 172 summarized in Table 3 . Focusing on the non-synonymous mutations, five amino acid changes were 173 identified (represented in bold). Of these, four amino acid changes were located on NSPs and one was 174 on S protein, as illustrated in the viral genome scheme of SARS-CoV-2 ( Figure 3 ). In order to assess 175 strain relatedness, the phylogenetic analysis was carried out. The isolates in this study were closely 176 related to the strain previously isolated in Japan (accession number BS000756.1; pango lineage 177 B.1.1.214), but not to any of the variants labeled by WHO (Figure 4) . 178

We hereby reported the single COVID-19 cluster population (cluster K) case in which the conventional 181 treatment was unsuccessful and the hospitalized patients became more severely ill, thus performed the 182 retrospective analysis to find out the causative factors. The patients in group B had a higher mortality 183 rate compared to group A, but no significant difference was indicated. For the severity of disease, the 184 patients in group B required higher oxygen flow rate in early course of admission. Furthermore, the 185 differences became larger when limited to males, with 41.2% of male severe patients in group B 186 against 6.3% in group A. 187

In terms of treatment strategies, we were likely to use methylprednisolone monotherapy for 188 severe cases in group B. This was because we had experienced that, in the winter of 2020, patients 189 who received methylprednisolone therapy appeared to have a better response than those who were 190 treated with remdesivir after poor response for dexamethasone, although the treatment guideline for 191 COVID-19 in Japan recommends the use of remdesivir for patients with pneumonia whose oxygen 192 saturation falls below 96% (https://www.mhlw.go.jp/content/000815065.pdf). In our study, there was 193 no significant difference of remdesivir usage between two groups, therefore the viral factors could 194 have an impact on the clinical outcomes. 195 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Position number based on alignment to NCBI reference sequence: NC_045512 (Wuhan-Hu-1).

The different parts between the two samples in group A are shown in a gray area. Amino acid changes identified between two groups were represented in bold.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

CKD is a key risk factor for COVID-19 mortality

Cancer patients in SARS-CoV-2 infection: 274 a nationwide analysis in China

Dexamethasone vs 277 methylprednisolone high dose for Covid-19 pneumonia

Establishment of a reverse genetics 280 system for SARS-CoV-2 using circular polymerase extension reaction

Freely available

Python tools for computational molecular biology and bioinformatics